Reticular Dysgenesis and Mitochondriopathy Induced by Adenylate Kinase 2 Deficiency with Atypical Presentation.
Adenylate Kinase
/ deficiency
Bone Marrow
/ pathology
Cell Membrane Permeability
Child, Preschool
Energy Metabolism
Fibroblasts
/ cytology
Homozygote
Humans
Leukopenia
/ diagnosis
Male
Mitochondria
/ metabolism
Mitochondrial Membranes
/ metabolism
Oxygen Consumption
Pedigree
Polymorphism, Single Nucleotide
Reactive Oxygen Species
/ metabolism
Severe Combined Immunodeficiency
/ diagnosis
Exome Sequencing
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 10 2019
31 10 2019
Historique:
received:
30
11
2018
accepted:
10
10
2019
entrez:
2
11
2019
pubmed:
2
11
2019
medline:
4
11
2020
Statut:
epublish
Résumé
Reticular dysgenesis is an autosomal recessive form of severe combined immunodeficiency (SCID) that usually manifests in newborns. It is a unique example of an immune deficiency that is linked to dysfunctional mitochondrial energy metabolism and caused by adenylate kinase 2 (AK2) deficiency. It is characterized by an early differentiation arrest in the myeloid lineage, impaired lymphoid maturation, and sensorineural hearing loss. In this study, a novel AK2 homozygous mutation, c.622 T > C [p.Ser208Pro], was identified in an Old Order Amish patient through whole exome sequencing. Functional studies showed that the patient's cells have no detectable AK2 protein, as well as low oxygen consumption rate (OCR), extracellular acidification rate (ECAR) and proton production rate (PPR). An increased production of reactive oxygen species, mitochondrial membrane permeability, and mitochondrial mass, and decreased ATP production, were also observed. The results confirm the pathogenicity of the AK2 mutation and demonstrate that reticular dysgenesis should be considered in Amish individuals presenting with immune deficiency. We also describe other pathophysiological aspects of AK2 deficiency not previously reported.
Identifiants
pubmed: 31673062
doi: 10.1038/s41598-019-51922-2
pii: 10.1038/s41598-019-51922-2
pmc: PMC6823482
doi:
Substances chimiques
Reactive Oxygen Species
0
Adenylate Kinase
EC 2.7.4.3
adenylate kinase 2
EC 2.7.4.3
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15739Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)
ID : 5 UL1 TR001857
Pays : International
Références
PLoS One. 2010 Oct 28;5(10):e13717
pubmed: 21060841
J Allergy Clin Immunol. 2014 Apr;133(4):1092-8
pubmed: 24290292
PLoS One. 2014 Aug 28;9(8):e106028
pubmed: 25165814
J Allergy Clin Immunol. 2013 Apr;131(4):1227-30, 1230.e1-3
pubmed: 23014587
Structure. 1996 Feb 15;4(2):147-56
pubmed: 8805521
J Med Invest. 2005 Aug;52(3-4):127-36
pubmed: 16167529
Blood. 2017 May 25;129(21):2928-2938
pubmed: 28331055
J Biol Chem. 2011 Feb 11;286(6):4081-9
pubmed: 20876536
Nat Genet. 2009 Jan;41(1):106-11
pubmed: 19043416
Mol Genet Metab. 2011 Apr;102(4):418-29
pubmed: 21237683
Cell Death Dis. 2015 Aug 13;6:e1856
pubmed: 26270350
J Immunol. 2017 Jan 15;198(2):640-644
pubmed: 27974455
Lancet. 2003 Feb 15;361(9357):553-60
pubmed: 12598139
J Allergy Clin Immunol. 2016 Jun;137(6):1780-1787
pubmed: 26915675
Biochem J. 2011 Feb 1;433(3):527-34
pubmed: 21080915
Int J Biochem Cell Biol. 2013 May;45(5):925-31
pubmed: 23416111
Cancer Res. 2012 Jun 1;72(11):2791-801
pubmed: 22472122
Nat Genet. 2009 Jan;41(1):101-5
pubmed: 19043417
Protein Sci. 1996 Mar;5(3):434-41
pubmed: 8868479